Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review)

Xu T, Wang X, Xin Y, Wang Z, Gong J, Zhang X, Li Y, Ji C, Sun Y, Zhao F, et al: Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II single-arm study and exploratory biomarker analysis. Cancer Res Treat. 55:626–635. 2023. View Article : Google Scholar :

Torka P, Groman A, Wong J, Nichols J, Kader A, Mavis C, Anampa-Guzmán A, Sait SJ, Block A, Przespolewski E, et al: Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL. Blood Adv. 7:1146–1155. 2023. View Article : Google Scholar

Yin Q, Shen J, Zhang Z, Yu H and Li Y: Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. Adv Drug Deliv Rev. 65:1699–1715. 2013. View Article : Google Scholar : PubMed/NCBI

Ruan T, Liu W, Tao K and Wu C: A review of research progress in multidrug-resistance mechanisms in gastric cancer. Onco Targets Ther. 13:1797–1807. 2020. View Article : Google Scholar : PubMed/NCBI

Lu C, Wei Y, Wang X, Zhang Z, Yin J, Li W, Chen L, Lyu X, Shi Z, Yan W and You Y: DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer. 19:282020. View Article : Google Scholar : PubMed/NCBI

Galle E, Thienpont B, Cappuyns S, Venken T, Busschaert P, Van Haele M, Van Cutsem E, Roskams T, van Pelt J, Verslype C, et al: DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer. Clin Epigenetics. 12:272020. View Article : Google Scholar : PubMed/NCBI

Leon G, MacDonagh L, Finn SP, Cuffe S and Barr MP: Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. Pharmacol Ther. 158:71–90. 2016. View Article : Google Scholar

Vitale D, Kumar Katakam S, Greve B, Jang B, Oh ES, Alaniz L and Götte M: Proteoglycans and glycosaminoglycans as regulators of cancer stem cell function and therapeutic resistance. FEBS J. 286:2870–2882. 2019. View Article : Google Scholar : PubMed/NCBI

Zhang H, Xu H, Ashby CR Jr, Assaraf YG, Chen ZS and Liu HM: Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp). Med Res Rev. 41:525–555. 2021. View Article : Google Scholar

Briz O, Perez-Silva L, Al-Abdulla R, Abete L, Reviejo M, Romero MR and Marin JJG: What 'the cancer genome atlas' database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs. Expert Opin Drug Metab Toxicol. 15:577–593. 2019. View Article : Google Scholar : PubMed/NCBI

He C, Sun Z, Hoffman RM, Yang Z, Jiang Y, Wang L and Hao Y: P-glycoprotein overexpression is associated with cisplatin resistance in human osteosarcoma. Anticancer Res. 39:1711–1718. 2019. View Article : Google Scholar : PubMed/NCBI

Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 455:152–162. 1976. View Article : Google Scholar : PubMed/NCBI

Ibrahim MAA, Abdeljawaad KAA, Jaragh-Alhadad LA, Oraby HF, Atia MAM, Alzahrani OR, Mekhemer GAH, Moustafa MF, Shawky AM, Sidhom PA and Abdelrahman AHM: Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: An in silico drug discovery study. J Biomol Struct Dyn. 1–16. 2023.Epub ahead of print.

Chang YT, Lin YC, Sun L, Liao WC, Wang CCN, Chou CY, Morris-Natschke SL, Lee KH and Hung CC: Wilforine resensitizes multidrug resistant cancer cells via competitive inhibition of P-glycoprotein. Phytomedicine. 71:1532392020. View Article : Google Scholar : PubMed/NCBI

Liu M, Xu C, Qin X, Liu W, Li D, Jia H, Gao X, Wu Y, Wu Q, Xu X, et al: DHW-221, a dual PI3K/mTOR inhibitor, overcomes multidrug resistance by targeting P-glycoprotein (P-gp/ABCB1) and Akt-mediated FOXO3a nuclear translocation in non-small cell lung cancer. Front Oncol. 12:8736492022. View Article : Google Scholar : PubMed/NCBI

Liu T, Wei R, Zhang Y, Chen W and Liu H: Association between NF-κB expression and drug resistance of liver cancer. Oncol Lett. 17:1030–1034. 2019.PubMed/NCBI

Liu Y, Cao F, Xia F, Li J, Dong X, Guo Y, Zhang J, Zhao Q and Liu Y: Shc3 facilitates breast cancer drug resistance by interacting with ErbB2 to initiate ErbB2/COX2/MDR1 axis. Cancer Med. 12:10768–10780. 2023. View Article : Google Scholar : PubMed/NCBI

Jeddi F, Soozangar N, Sadeghi MR, Somi MH, Shirmohamadi M, Eftekhar-Sadat AT and Samadi N: Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer. Biomed Pharmacother. 97:286–292. 2018. View Article : Google Scholar

Chen Q, Liu X, Luo Z, Wang S, Lin J, Xie Z, Li M, Li C, Cao H, Huang Q, et al: Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression. J Cell Physiol. 234:6611–6623. 2019. View Article : Google Scholar

Mai L, Luo M, Wu JJ, Yang JH and Hong LY: The combination therapy of HIF1α inhibitor LW6 and cisplatin plays an effective role on anti-tumor function in A549 cells. Neoplasma. 66:776–784. 2019. View Article : Google Scholar : PubMed/NCBI

Ren H, Wang Z, Chen Y, Liu Y, Zhang S, Zhang T and Li Y: SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway. Onco Targets Ther. 12:2585–2594. 2019. View Article : Google Scholar : PubMed/NCBI

Yamamoto M, Suzuki S, Togashi K, Sanomachi T, Seino S, Kitanaka C and Okada M: AS602801 sensitizes ovarian cancer stem cells to paclitaxel by down-regulating MDR1. Anticancer Res. 39:609–617. 2019. View Article : Google Scholar : PubMed/NCBI

Gao J, Hou D, Hu P and Mao G: Curcumol increases the sensitivity of colon cancer to 5-FU by regulating Wnt/β-catenin signaling. Transl Cancer Res. 10:2437–2450. 2021. View Article : Google Scholar

Li M, Li ZH, Song J, Li X, Zhai P, Mu X, Qiu F and Yao L: miR-205 Reverses MDR-1 mediated doxorubicin resistance via PTEN in human liver cancer HepG2 cells. Cell J. 24:112–119. 2022.PubMed/NCBI

Zhang L, Li Y, Hu C, Chen Y, Chen Z, Chen ZS, Zhang JY and Fang S: CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells. Mol Cancer. 21:1032022. View Article : Google Scholar : PubMed/NCBI

Wan Y, Chen Z, Wang Y, Zhao W, Pei Z, Pu L, Lv Y, Li J, Li J and Pei Y: A hyaluronic acid modified cuprous metal-organic complex for reversing multidrug resistance via redox dyshomeostasis. Carbohydr Polym. 311:1207622023. View Article : Google Scholar : PubMed/NCBI

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI

Abou-Alfa GK: Selection of patients with hepatocellular carcinoma for sorafenib. J Natl Compr Canc Netw. 7:397–403. 2009. View Article : Google Scholar : PubMed/NCBI

Xia X, Wang Q, Ye T, Liu Y, Liu D, Song S and Zheng C: NRF2/ABCB1-mediated efflux and PARP1-mediated dampening of DNA damage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells. Fundam Clin Pharmacol. 34:41–50. 2020. View Article : Google Scholar

Yuan P, Zheng A and Tang Q: Tripartite motif protein 25 is associated with epirubicin resistance in hepatocellular carcinoma cells via regulating PTEN/AKT pathway. Cell Biol Int. 44:1503–1513. 2020. View Article : Google Scholar : PubMed/NCBI

Mou SJ, Yang PF, Liu YP, Xu N, Jiang WW and Yue WJ: BCLAF1 promotes cell proliferation, invasion and drug-resistance though targeting lncRNA NEAT1 in hepatocellular carcinoma. Life Sci. 242:1171772020. View Article : Google Scholar

Fang Z, Chen W, Yuan Z, Liu X and Jiang H: LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 101:536–542. 2018. View Article : Google Scholar : PubMed/NCBI

Zhao L, Bin S, He HL, Yang JM, Pu YC, Gao CH, Wang H and Wang BL: Sodium butyrate increases P-gp expression in lung cancer by upregulation of STAT3 and mRNA stabilization of ABCB1. Anticancer Drugs. 29:227–233. 2018. View Article : Google Scholar : PubMed/NCBI

Zhu J, Hu W, Zhang Y, Du P, Xiao W and Li Y: Comparison of survival outcomes of chemotherapy plus surgery vs chemotherapy alone for patients with isolated liver metastases from gallbladder carcinoma. Am Surg. 89:676–684. 2023. View Article : Google Scholar

Wu D, Liu L, Yan X, Wang C, Wang Y, Han K, Lin S, Gan Z and Min D: Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein. Oncotarget. 8:63857–63870. 2017. View Article : Google Scholar : PubMed/NCBI

Yang JZ, Huang LH, Chen R, Meng LJ, Gao YY, Ji QY and Wang Y: LIM kinase 1 serves an important role in the multidrug resistance of osteosarcoma cells. Oncol Lett. 15:250–256. 2018.PubMed/NCBI

Liu S, Chen S, Yuan W, Wang H, Chen K and Li D and Li D: PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways. Oncotarget. 8:99901–99912. 2017. View Article : Google Scholar : PubMed/NCBI

Chen S, Wang H, Li Z, You J, Wu QW, Zhao C, Tzeng CM and Zhang ZM: Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription. Br J Cancer. 119:182–192. 2018. View Article : Google Scholar : PubMed/NCBI

Lim JS, Jung GY and Park SY: Nkx-2.5 regulates MDR1 expression via its upstream promoter in breast cancer cells. J Korean Med Sci. 34:e1002019. View Article : Google Scholar : PubMed/NCBI

Baltes F, Pfeifer V, Silbermann K, Caspers J, Wantoch von Rekowski K, Schlesinger M and Bendas G: β₁-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. Biochim Biophys Acta Mol Cell Res. 1867:1186632020. View Article : Google Scholar

Li G, Guo J, Shen BQ, Yadav DB, Sliwkowski MX, Crocker LM, Lacap JA and Phillips GDL: Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol Cancer Ther. 17:1441–1453. 2018. View Article : Google Scholar : PubMed/NCBI

Tang H, Zeng L, Wang J, Zhang X, Ruan Q, Wang J, Cui S and Yang D: Reversal of 5-fluorouracil resistance by EGCG is mediate by inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer. Oncotarget. 8:82842–82853. 2017. View Article : Google Scholar : PubMed/NCBI

Deng XJ, Zheng HL, Ke XQ, Deng M, Ma ZZ, Zhu Y and Cui YY: Hsa-miR-34a-5p reverses multidrug resistance in gastric cancer cells by targeting the 3′-UTR of SIRT1 and inhibiting its expression. Cell Signal. 84:1100162021. View Article : Google Scholar

Xu YD, Shang J, Li M and Zhang YY: LncRNA DANCR accelerates the development of multidrug resistance of gastric cancer. Eur Rev Med Pharmacol Sci. 23:2794–2802. 2019.PubMed/NCBI

Zhang X, Bo P, Liu L, Zhang X and Li J: Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed Pharmacother. 92:580–585. 2017. View Article : Google Scholar : PubMed/NCBI

Tan B, Li Y, Zhao Q, Fan L and Wang D: ZNF139 increases multidrug resistance in gastric cancer cells by inhibiting miR-185. Biosci Rep. 38:BSR201810232018. View Article : Google Scholar : PubMed/NCBI

Yan X, Zhao J and Zhang R: Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1). Cancer Chemother Pharmacol. 80:395–403. 2017. View Article : Google Scholar : PubMed/NCBI

Gao Z, Li Z, Liu Y and Liu Z: Forkhead box O3 promotes colon cancer proliferation and drug resistance by activating MDR1 expression. Mol Genet Genomic Med. 7:e5542019. View Article : Google Scholar : PubMed/NCBI

Du J, He Y, Li P, Wu W, Chen Y and Ruan H: IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1). Cancer Chemother Pharmacol. 81:1111–1119. 2018. View Article : Google Scholar : PubMed/NCBI

Zhang S, Chatterjee T, Godoy C, Wu L, Liu QJ and Carmon KS: GPR56 drives colorectal tumor growth and promotes drug resistance through upregulation of MDR1 expression via a RhoA-mediated mechanism. Mol Cancer Res. 17:2196–2207. 2019. View Article : Google Scholar : PubMed/NCBI

Sui M, Yang H, Guo M, Li W, Gong Z, Jiang J and Li P: Cajanol sensitizes A2780/Taxol cells to paclitaxel by inhibiting the PI3K/Akt/NF-κB signaling pathway. Front Pharmacol. 12:7833172021. View Article : Google Scholar

Zhao P, Wang S, Jiang J, Liu H, Zhu X, Zhao N, Li J, Yin Y, Pan X, Yang X, et al: TIPE2 sensitizes osteosarcoma cells to cis-platin by down-regulating MDR1 via the TAK1-NF-κB and-AP-1 pathways. Mol Immunol. 101:471–478. 2018. View Article : Google Scholar : PubMed/NCBI

Song W, Liang C, Sun Y, Morii S, Yomogida S, Isaji T, Fukuda T, Hang Q, Hara A, Nakano M and Gu J: Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: Involvement of the TNFR2-NF-κB signaling pathway. J Biol Chem. 299:1030512023. View Article : Google Scholar

Liu K, Song J, Yan Y, Zou K, Che Y, Wang B, Li Z, Yu W, Guo W, Zou L, et al: Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway. Transl Oncol. 14:1008762021. View Article : Google Scholar

Liu RM, Xu P, Chen Q, Feng SL and Xie Y: A multiple-targets alkaloid nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo. Phytomedicine. 79:1533422020. View Article : Google Scholar : PubMed/NCBI

Wang H, Jia XH, Chen JR, Wang JY and Li YJ: Osthole shows the potential to overcome P-glycoprotein-mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway. Oncol Rep. 35:3659–3668. 2016. View Article : Google Scholar : PubMed/NCBI

Satonaka H, Ishida K, Takai M, Koide R, Shigemasa R, Ueyama J, Ishikawa T, Hayashi K, Goto H and Wakusawa S: (-)-Epigallocatechin-3-gallate down-regulates doxorubicin-induced overexpression of P-glycoprotein through the coordinate inhibition of PI3K/Akt and MEK/ERK signaling pathways. Anticancer Res. 37:6071–6077. 2017.PubMed/NCBI

Ding Y, Zhen Z, Nisar MA, Ali F, Din RU, Khan M, Mughal TA, Alam G, Liu L and Saleem MZ: Sesquiterpene lactones attenuate paclitaxel resistance via inhibiting MALAT1/STAT3/FUT4 Axis and P-glycoprotein transporters in lung cancer cells. Front Pharmacol. 13:7956132022. View Article : Google Scholar

Wang PP, Luan JJ, Xu WK, Wang L, Xu DJ, Yang CY, Zhu YH and Wang YQ: Astragaloside IV downregulates the expression of MDR1 in Bel-7402/FU human hepatic cancer cells by inhibiting the JNK/c-Jun/AP-1 signaling pathway. Mol Med Rep. 16:2761–2766. 2017. View Article : Google Scholar : PubMed/NCBI

Qin T, Zhu W, Kan X, Li L and Wu D: Luteolin attenuates the chemoresistance of osteosarcoma through inhibiting the PTN/β-catenin/MDR1 signaling axis by upregulating miR-384. J Bone Oncol. 34:100429–34. 2022. View Article : Google Scholar

Li L, Fu Q, Xia M, Xin L, Shen H, Li G, Ji G, Meng Q and Xie Y: Inhibition of P-glycoprotein mediated efflux in Caco-2 cells by phytic acid. J Agric Food Chem. 66:988–998. 2018. View Article : Google Scholar

Mirzaei SA, Reiisi S, Ghiasi Tabari P, Shekari A, Aliakbari F, Azadfallah E and Elahian F: Broad blocking of MDR efflux pumps by acetylshikonin and acetoxyisovalerylshikonin to generate hypersensitive phenotype of malignant carcinoma cells. Sci Rep. 8:34462018. View Article : Google Scholar : PubMed/NCBI

Shen X, Chen G, Zhu G and Fong WF: (+/−)-3′-O, 4′-O-dicynnamoyl-cis-khellactone, a derivative of (+/−)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells. Bioorg Med Chem. 14:7138–7145. 2006. View Article : Google Scholar : PubMed/NCBI

Bai Z, Zhou Q, Zhu H, Ye X, Wu P and Ma L: QTMP, a novel thiourea polymer, causes DNA damage to exert anticancer activity and overcome multidrug resistance in colorectal cancer cells. Front Oncol. 11:6676892021. View Article : Google Scholar : PubMed/NCBI

Gao M, Liu T, Li J, Guan Q, Wang H, Yan S, Li Z, Zuo D, Zhang W and Wu Y: YAN, a novel microtubule inhibitor, inhibits P-gp and MRP1 function and induces mitotic slippage followed by apoptosis in multidrug-resistant A549/Taxol cells. Toxicol In Vitro. 69:1049712020. View Article : Google Scholar : PubMed/NCBI

Wu CP, Murakami M, Wu YS, Chi YC, Hsiao SH, Huang YH, Hung TH and Ambudkar SV: Branebrutinib (BMS-986195), a bruton's tyrosine kinase inhibitor, resensitizes P-glycoprotein-overexpressing multidrug-resistant cancer cells to chemotherapeutic agents. Front Cell Dev Biol. 9:6995712021. View Article : Google Scholar : PubMed/NCBI

Podolski-Renić A, Dinić J, Stanković T, Tsakovska I, Pajeva I, Tuccinardi T, Botta L, Schenone S and Pešić M: New therapeutic strategy for overcoming multidrug resistance in cancer cells with pyrazolo[3,4-d]pyrimidine tyrosine kinase inhibitors. Cancers (Basel). 13:53082021. View Article : Google Scholar

Wu CP, Hung TH, Lusvarghi S, Chu YH, Hsiao SH, Huang YH, Chang YT and Ambudkar SV: The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. Biochem Pharmacol. 188:1145162021. View Article : Google Scholar : PubMed/NCBI

Zhang L, Ye B, Lin Y, Li YD, Wang JQ, Chen Z, Ping FF and Chen ZS: Ribociclib inhibits P-gp-mediated multidrug resistance in human epidermoid carcinoma cells. Front Pharmacol. 13:8671282022. View Article : Google Scholar : PubMed/NCBI

Laiolo J, Barbieri CL, Joray MB, Lanza PA, Palacios SM, Vera DMA and Carpinella MC: Plant extracts and betulin from Ligaria cuneifolia inhibit P-glycoprotein function in leukemia cells. Food Chem Toxicol. 147:1119222021. View Article : Google Scholar

Liu Z, Wen X, Wang G and Zhou Y: Involvement of P-gp on reversing multidrug resistance effects of 23-hydroxybetulinic acid on chemotherapeutic agents. Front Pharmacol. 12:7967452021. View Article : Google Scholar :

Yang T, Wang S, Li H, Zhao Q, Yan S, Dong M, Liu D, Chen X and Li R: Lathyrane diterpenes from Euphorbia lathyris and the potential mechanism to reverse the multi-drug resistance in HepG2/ADR cells. Biomed Pharmacother. 121:1096632020. View Article : Google Scholar

Qian J, Xia M, Liu W, Li L, Yang J, Mei Y, Meng Q and Xie Y: Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Eur J Pharmacol. 852:231–243. 2019. View Article : Google Scholar : PubMed/NCBI

Teng YN, Lin KI, Lin YC, Thang TD, Lan YH and Hung CC: A novel flavonoid from Fissistigma cupreonitens, 5-hydroxy-7,8-dimethoxyflavanone, competitively inhibited the efflux function of human P-glycoprotein and reversed cancer multi-drug resistance. Phytomedicine. 85:1535282021. View Article : Google Scholar

Min H, Niu M, Zhang W, Yan J, Li J, Tan X, Li B, Su M, Di B and Yan F: Emodin reverses leukemia multidrug resistance by competitive inhibition and downregulation of P-glycoprotein. PLoS One. 12:e01879712017. View Article : Google Scholar : PubMed/NCBI

Pellegrini E, Multari G, Gallo FR, Vecchiotti D, Zazzeroni F, Condello M and Meschini S: A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells. Toxicol Appl Pharmacol. 434:1158162022. View Article : Google Scholar

Sagnou M, Novikov FN, Ivanova ES, Alexiou P, Stroylov VS, Titov IY, Tatarskiy VV, Vagida MS, Pelecanou M, Shtil AA and Chilov GG: Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin. Eur J Med Chem. 198:1123312020. View Article : Google Scholar : PubMed/NCBI

Creemers SG, van Koetsveld PM, De Herder WW, Dogan F, Franssen GJH, Feelders RA and Hofland LJ: MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer. Endocr Relat Cancer. 26:367–378. 2019. View Article : Google Scholar : PubMed/NCBI

Wang SQ, Teng QX, Wang S, Lei ZN, Hu HH, Lv HF, Chen BB, Wang JZ, Shi XJ, Xu WF, et al: Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor. Acta Pharm Sin B. 12:3263–3280. 2022. View Article : Google Scholar : PubMed/NCBI

Dei S, Coronnello M, Bartolucci G, Manetti D, Romanelli MN, Udomtanakunchai C, Salerno M and Teodori E: Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents. Eur J Med Chem. 147:7–20. 2018. View Article : Google Scholar : PubMed/NCBI

Qiu Q, Zou F, Li H, Shi W, Zhou D, Zhang P, Li T, Yin Z, Cai Z, Jiang Y, et al: Structure-based discovery of pyrimidine aminobenzene derivatives as potent oral reversal agents against P-gp- and BCRP-mediated multidrug resistance. J Med Chem. 64:6179–6197. 2021. View Article : Google Scholar : PubMed/NCBI

Li YS, Yang X, Zhao DS, Cai Y, Huang Z, Wu R, Wang SJ, Liu GJ, Wang J, Bao XZ, et al: Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell. Eur J Med Chem. 216:1133362021. View Article : Google Scholar : PubMed/NCBI

Yuan S, Wang B, Dai QQ, Zhang XN, Zhang JY, Zuo JH, Liu H, Chen ZS, Li GB, Wang S, et al: Discovery of new 4-indolyl quinazoline derivatives as highly potent and orally bioavailable P-glycoprotein inhibitors. J Med Chem. 64:14895–14911. 2021. View Article : Google Scholar : PubMed/NCBI

Wang H, Wang X, Liao A and Liu Z: Hypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway. Mol Cell Biochem. 433:141–148. 2017. View Article : Google Scholar : PubMed/NCBI

Snyder S, Murundi S, Crawford L and Putnam D: Enabling P-glycoprotein inhibition in multidrug resistant cancer through the reverse targeting of a quinidine-PEG conjugate. J Control Release. 317:291–299. 2020. View Article : Google Scholar

Zhang H, Bian S, Xu Z, Gao M, Wang H, Zhang J, Zhang M, Ke Y, Wang W, Chen ZS and Xu H: The effect and mechanistic study of encequidar on reversing the resistance of SW620/AD300 cells to doxorubicin. Biochem Pharmacol. 205:1152582022. View Article : Google Scholar : PubMed/NCBI

Xu SW, Law BYK, Qu SLQ, Hamdoun S, Chen J, Zhang W, Guo JR, Wu AG, Mok SWF, Zhang DW, et al: SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells. Pharmacol Res. 153:1046602020. View Article : Google Scholar : PubMed/NCBI

Rauf A, Uddin G, Raza M, Ahmad B, Jehan N, Siddiqui BS, Molnar J, Csonka A and Szabo D: Reversal of multidrug resistance in mouse lymphoma cells by extracts and flavonoids from Pistacia integerrima. Asian Pac J Cancer Prev. 17:51–55. 2016. View Article : Google Scholar : PubMed/NCBI

Giorgi C, Gasser UE, Lafont ME, Holzgang HE and Thalhammer VF: Inhibition of chemoresistance in primary tumor cells by Camellia sinensis non fermentatum extract noviphenone (NPE^®). Anticancer Res. 39:4101–4110. 2019. View Article : Google Scholar : PubMed/NCBI

Kawami M, Yamada Y, Issarachot O, Junyaprasert VB, Yumoto R and Takano M: P-gp modulating effect of Azadirachta indica extract in multidrug-resistant cancer cell lines. Pharmazie. 73:104–109. 2018.PubMed/NCBI

Zheng Y, Su C, Zhao L and Shi Y: mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy. J Nanobiotechnology. 15:662017. View Article : Google Scholar : PubMed/NCBI

Chen Z, Pan T, Jiang D, Jin L, Geng Y, Feng X, Shen A and Zhang L: The lncRNA-GAS5/miR-221-3p/DKK2 axis modulates ABCB1-mediated adriamycin resistance of breast cancer via the Wnt/β-catenin signaling pathway. Mol Ther Nucleic Acids. 19:1434–1448. 2020. View Article : Google Scholar : PubMed/NCBI

Han Z and Shi L: Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem Biophys Res Commun. 495:947–953. 2018. View Article : Google Scholar

Kang Y, Zhang S, Cao W, Wan D and Sun L: Knockdown of LncRNA CRNDE suppresses proliferation and P-glycoprotein-mediated multidrug resistance in acute myelocytic leukemia through the Wnt/β-catenin pathway. Biosci Rep. 40:BSR201934502020. View Article : Google Scholar

Zou H and Li H: Knockdown of long non-coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells. Exp Ther Med. 18:4510–4516. 2019.PubMed/NCBI

Zou Z, Zou R, Zong D, Shi Y, Chen J, Huang J, Zhu J, Chen L, Bao X, Liu Y, et al: miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med. 21:1929–1943. 2017. View Article : Google Scholar : PubMed/NCBI

Zhao Y, Qi X, Chen J, Wei W, Yu C, Yan H, Pu M, Li Y, Miao L, Li C and Ren J: The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma. Cancer Lett. 408:102–111. 2017. View Article : Google Scholar : PubMed/NCBI

Yi D, Xu L, Wang R, Lu X and Sang J: miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biol Int. 43:12–21. 2019. View Article : Google Scholar

Zheng SZ, Sun P, Wang JP, Liu Y, Gong W and Liu J: MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells. World J Gastroenterol. 25:2752–2762. 2019. View Article : Google Scholar : PubMed/NCBI

Wei S, Gao J, Zhang M, Dou Z, Li W and Zhao L: Dual delivery nanoscale device for miR-451 and adriamycin co-delivery to combat multidrug resistant in bladder cancer. Biomed Pharmacother. 122:1094732020. View Article : Google Scholar : PubMed/NCBI

Kenworthy R, Bosco DB, DeLigio JT and Zorio DAR: Micro-RNA149 confers taxane resistance to malignant mesothelioma cells via regulation of P-glycoprotein expression. Cancer Biol Ther. 19:181–187. 2018. View Article : Google Scholar :

Wang S, Guo J, Mo Z, Shi X and Qu C: Clinical significance and correlation of miR-200c and P-gp expression in gastric cancer and the effects on multidrug resistance. J Gastrointest Oncol. 13:581–592. 2022. View Article : Google Scholar : PubMed/NCBI

Cao F and Yin LX: miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway. Exp Mol Pathol. 106:34–43. 2019. View Article : Google Scholar

Sousa D, Matthiesen R, Lima RT and Vasconcelos MH: Deep sequencing analysis reveals distinctive non-coding RNAs when comparing tumor multidrug-resistant cells and extracellular vesicles with drug-sensitive counterparts. Cancers (Basel). 12:2002020. View Article : Google Scholar : PubMed/NCBI

Shi X, Valizadeh A, Mir SM, Asemi Z, Karimian A, Majidina M, Safa A and Yosefi B: miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells. Eur J Pharmacol. 880:1731382020. View Article : Google Scholar : PubMed/NCBI

Xie B, Li L, Zhang Z, Zhao L, Cheng J, Zhou C, Cheng J, Yan J, Chen J, Yi J, et al: MicroRNA-1246 by targeting AXIN2 and GSK-3β overcomes drug resistance and induces apoptosis in chemo-resistant leukemia cells. J Cancer. 12:4196–4208. 2021. View Article : Google Scholar :

Kara G, Calin GA and Ozpolat B: RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 182:1141132022. View Article : Google Scholar : PubMed/NCBI

Yalamarty SSK, Filipczak N, Li X, Pathrikar TV, Cotter C and Torchilin VP: Co-delivery of siRNA and chemotherapeutic drug using 2C5 antibody-targeted dendrimer-based mixed micelles for multidrug resistant cancers. Pharmaceutics. 14:14702022. View Article : Google Scholar : PubMed/NCBI

Wang C, Guan W, Peng J, Chen Y, Xu G and Dou H: Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors. Acta Biomater. 103:247–258. 2020. View Article : Google Scholar

Jiang Y, Liu Y, Wang M, Li Z, Su L, Xu X, Xing C, Li J, Lin L, Lu C and Yang H: siRNA-based carrier-free system for synergistic chemo/chemodynamic/RNAi therapy of drug-resistant tumors. ACS Appl Mater Interfaces. 14:361–372. 2022. View Article : Google Scholar

Yang X, Wang Y, Chen S, Zhang S and Cui C: Cetuximab-modified human serum albumin nanoparticles co-loaded with doxorubicin and MDR1 siRNA for the treatment of drug-resistant breast tumors. Int J Nanomedicine. 16:7051–7069. 2021. View Article : Google Scholar : PubMed/NCBI

Liu H, Ma D, Chen J, Ye L, Li Y, Xie Y, Zhao X, Zou H, Chen X, Pu J and Liu P: A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer. Nano Res. 15:6306–6314. 2022. View Article : Google Scholar

Wu J, Wang Q, Dong X, Xu M, Yang J, Yi X, Chen B, Dong X, Wang Y, Lou X, et al: Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer. Theranostics. 11:3710–3724. 2021. View Article : Google Scholar : PubMed/NCBI

Zhang J, Du Z, Pan S, Shi M, Li J, Yang C, Hu H, Qiao M, Chen D and Zhao X: Overcoming multidrug resistance by codelivery of MDR1-targeting siRNA and doxorubicin using EphA10-mediated pH-sensitive lipoplexes: In vitro and in vivo evaluation. ACS Appl Mater Interfaces. 10:21590–21600. 2018. View Article : Google Scholar : PubMed/NCBI

Cao X, Li R, Xiong H, Su J, Guo C, An T, Zong H and Zhao R: Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein. Eur J Med Chem. 221:1135202021. View Article : Google Scholar : PubMed/NCBI

Liu ZL, Jin BJ, Cheng CG, Zhang FX, Wang SW, Wang Y and Wu B: Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway. Eur Rev Med Pharmacol Sci. 21:5370–5377. 2017.PubMed/NCBI

Ji L, Liu X, Zhang S, Tang S, Yang S, Li S, Qi X, Yu S, Lu L, Meng X and Liu Z: The novel triazolonaphthalimide derivative LSS-11 synergizes the anti-proliferative effect of paclitaxel via STAT3-dependent MDR1 and MRP1 downregulation in chemoresistant lung cancer cells. Molecules. 22:18222017. View Article : Google Scholar : PubMed/NCBI

Zhang L, Li Y, Wang Q, Chen Z, Li X, Wu Z, Hu C, Liao D, Zhang W and Chen ZS: The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol Cancer. 19:102020. View Article : Google Scholar

Liu T, Peng Y, Li X, Liu L, Liu F and He L: A novel delocalized lipophilic cation-chlorambucil conjugate inhibits P-glycoprotein in HepG2/ADM cells. Bioorg Med Chem. 25:5461–5467. 2017. View Article : Google Scholar : PubMed/NCBI

Ganesan M, Kanimozhi G, Pradhapsingh B, Khan HA, Alhomida AS, Ekhzaimy A, Brindha GR and Prasad NR: Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways. Biomed Pharmacother. 139:1116322021. View Article : Google Scholar : PubMed/NCBI

Li Y, Li X, Lu Y, Chaurasiya B, Mi G, Shi D, Chen D, Webster TJ, Tu J and Shen Y: Co-delivery of Poria cocos extract and doxorubicin as an 'all-in-one' nanocarrier to combat breast cancer multidrug resistance during chemotherapy. Nanomedicine. 23:1020952020. View Article : Google Scholar

Ye Q, Liu K, Shen Q, Li Q, Hao J, Han F and Jiang RW: Reversal of multidrug resistance in cancer by multi-functional flavonoids. Front Oncol. 9:4872019. View Article : Google Scholar : PubMed/NCBI

Fang Y, Liang F, Xia M, Cao W, Pan S, Wu T and Xu X: Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells. Food Chem Toxicol. 155:1123812021. View Article : Google Scholar : PubMed/NCBI

Kong W, Ling X, Chen Y, Wu X, Zhao Z, Wang W, Wang S, Lai G and Yu Z: Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway. Int J Mol Med. 45:1213–1224. 2020.PubMed/NCBI

La X, Zhang L, Li Z, Li H and Yang Y: (-)-Epigallocatechin gallate (EGCG) enhances the sensitivity of colorectal cancer cells to 5-FU by inhibiting GRP78/NF-κB/miR-155-5p/MDR1 pathway. J Agric Food Chem. 67:2510–2518. 2019. View Article : Google Scholar : PubMed/NCBI

Mohana S, Ganesan M, Rajendra Prasad N, Ananthakrishnan D and Velmurugan D: Flavonoids modulate multidrug resistance through wnt signaling in P-glycoprotein overexpressing cell lines. BMC Cancer. 18:11682018. View Article : Google Scholar : PubMed/NCBI

Wang ZD, Wang RZ, Xia YZ, Kong LY and Yang L: Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells. Chin J Nat Med. 16:20–28. 2018.PubMed/NCBI

Wang F, Huang N, Yang Q, Liu J and Chen J: Reversal of doxorubicin-resistance by Salvia miltiorrhiza ligustrazine in the SHG44/doxorubicin glioma drug-resistant cell line. Oncol Lett. 14:4708–4714. 2017. View Article : Google Scholar : PubMed/NCBI

Zhou P, Zhang R, Wang Y, Xu D, Zhang L, Qin J, Su G, Feng Y, Chen H, You S, et al: Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals. Oncotarget. 8:111144–111160. 2017. View Article : Google Scholar

Zhou X, Jin N and Chen B: Tetrandrine overcomes drug resistance mediated by bone marrow microenvironment by regulating the expression of P-glycoprotein in acute leukemia. Hematology. 27:274–279. 2022. View Article : Google Scholar : PubMed/NCBI

Qian K, Tang CY, Chen LY, Zheng S, Zhao Y, Ma LS, Xu L, Fan LH, Yu JD, Tan HS, et al: Berberine reverses breast cancer multidrug resistance based on fluorescence pharmacokinetics in vitro and in vivo. ACS Omega. 6:10645–10654. 2021. View Article : Google Scholar : PubMed/NCBI

Huang CZ, Wang YF, Zhang Y, Peng YM, Liu YX, Ma F, Jiang JH and Wang QD: Cepharanthine hydrochloride reverses P-glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway. Oncol Rep. 38:2558–2564. 2017. View Article : Google Scholar : PubMed/NCBI

Liao D, Zhang W, Gupta P, Lei ZN, Wang JQ, Cai CY, Vera AA, Zhang L, Chen ZS and Yang DH: Tetrandrine interaction with ABCB1 reverses multidrug resistance in cancer cells through competition with anti-cancer drugs followed by downregulation of ABCB1 expression. Molecules. 24:43832019. View Article : Google Scholar : PubMed/NCBI

Quarti J, Torres DNM, Ferreira E, Vidal RS, Casanova F, Chiarini LB, Fialho E and Rumjanek VM: Selective cytotoxicity of piperine over multidrug resistance leukemic cells. Molecules. 26:9342021. View Article : Google Scholar : PubMed/NCBI

Wang SQ, Li X, Wang XN and Lou HX: Reversal of P-glycoprotein-mediated multidrug resistance in human leukemia cell line K562/A02 by archangelicin. Chin J Nat Med. 9:146–150. 2011.

Sharma P, Tyagi A, Bhansali P, Pareek S, Singh V, Ilyas A, Mishra R and Poddar NK: Saponins: Extraction, bio-medicinal properties and way forward to anti-viral representatives. Food Chem Toxicol. 150:1120752021. View Article : Google Scholar : PubMed/NCBI

Li Y, Sun Y, Tang T, Niu Y, Li X, Xie M, Jin H and Mei Q: Paris saponin VII reverses chemoresistance in breast MCF-7/ADR cells. J Ethnopharmacol. 232:47–54. 2019. View Article : Google Scholar

Niu X, Shi Y, Li Q, Chen H, Fan X, Yu Y, Lv C and Lu J: Ginsenoside Rb₁ for overcoming cisplatin-insensitivity of A549/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1. Phytomedicine. 115:1547762023. View Article : Google Scholar

Li J, Zheng L, Wang R, Sun D, Liang S, Wu J, Liu Y, Tian X, Li T, Yang Y and Han L: Synergistic combination of sodium aescinate-stabilized, polymer-free, twin-like nanoparticles to reverse paclitaxel resistance. Int J Nanomedicine. 15:5839–5853. 2020. View Article : Google Scholar : PubMed/NCBI

Huang C, Xu D, Xia Q, Wang P, Rong C and Su Y: Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by astragaloside II. J Pharm Pharmacol. 64:1741–1750. 2012. View Article : Google Scholar : PubMed/NCBI

Wang PP, Xu DJ, Huang C, Wang WP and Xu WK: Astragaloside IV reduces the expression level of P-glycoprotein in multidrug-resistant human hepatic cancer cell lines. Mol Med Rep. 9:2131–2137. 2014. View Article : Google Scholar : PubMed/NCBI

Liu GW, Liu YH, Jiang GS and Ren WD: The reversal effect of ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. Hum Cell. 31:189–198. 2018. View Article : Google Scholar : PubMed/NCBI

Liu C, Gong Q, Chen T, Lv J, Feng Z, Liu P and Deng Z: Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors. Oncol Lett. 15:4376–4382. 2018.PubMed/NCBI

Sadava D and Kane SE: Silibinin reverses drug resistance in human small-cell lung carcinoma cells. Cancer Lett. 339:102–106. 2013. View Article : Google Scholar : PubMed/NCBI

Dobiasová S, Řehořová K, Kučerová D, Biedermann D, Káňová K, Petrásková L, Koucká K, Václavíková R, Valentová K, Ruml T, et al: Multidrug resistance modulation activity of silybin derivatives and their anti-inflammatory potential. Antioxidants (Basel). 9:4552020. View Article : Google Scholar : PubMed/NCBI

Zhang ZL, Jiang QC and Wang SR: Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation. Breast Cancer. 25:233–242. 2018. View Article : Google Scholar

Liao XZ, Gao Y, Sun LL, Liu JH, Chen HR, Yu L, Chen ZZ, Chen WH and Lin LZ: Rosmarinic acid reverses non-small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway. Phytother Res. 34:1142–1153. 2020. View Article : Google Scholar : PubMed/NCBI

Muthusamy G, Gunaseelan S and Prasad NR: Ferulic acid reverses P-glycoprotein-mediated multidrug resistance via inhibition of PI3K/Akt/NF-κB signaling pathway. J Nutr Biochem. 63:62–71. 2019. View Article : Google Scholar

Oh SS, Lee KW, Madhi H, Jeong JW, Park S, Kim M, Lee Y, Han HT, Hwangbo C, Yoo J and Kim KD: Cordycepin resensitizes T24R2 cisplatin-resistant human bladder cancer cells to cisplatin by inactivating Ets-1 dependent MDR1 transcription. Int J Mol Sci. 21:17102020. View Article : Google Scholar : PubMed/NCBI

Sawicka E, Saczko J, Kulbacka J, Szydełko M, Szymańska B and Piwowar A: The influence of interaction between cadmium with 17β-estradiol, 2-methoxyestradiol and 16α-hydroxyestrone on viability and P-glycoprotein in ovarian cancer cell line. Int J Mol Sci. 23:26282022. View Article : Google Scholar

Ding Y, Fan J, Fan Z and Zhang K: γ-Tocotrienol reverses multidrug resistance of breast cancer cells through the regulation of the γ-Tocotrienol-NF-κB-P-gp axis. J Steroid Biochem Mol Biol. 209:1058352021. View Article : Google Scholar

Fujihara T, Mizobuchi Y, Nakajima K, Kageji T, Matsuzaki K, Kitazato KT, Otsuka R, Hara K, Mure H, Okazaki T, et al: Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model. J Neurooncol. 139:323–332. 2018. View Article : Google Scholar : PubMed/NCBI

Norouzi-Barough L, Sarookhani M, Salehi R, Sharifi M and Moghbelinejad S: CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line. Iran J Basic Med Sci. 21:181–187. 2018.PubMed/NCBI

Peng H, Qiao L, Shan G, Gao M, Zhang R, Yi X and He X: Stepwise responsive carboxymethyl chitosan-based nanoplatform for effective drug-resistant breast cancer suppression. Carbohydr Polym. 291:1195542022. View Article : Google Scholar : PubMed/NCBI

Teng YN, Wang CCN, Liao WC, Lan YH and Hung CC: Caffeic acid attenuates multi-drug resistance in cancer cells by inhibiting efflux function of human P-glycoprotein. Molecules. 25:2472020. View Article : Google Scholar : PubMed/NCBI

Ma Y, Wen J, Wang J, Wang C, Zhang Y, Zhao L, Li J and Feng X: Asiaticoside antagonizes proliferation and chemotherapeutic drug resistance in hepatocellular carcinoma (HCC) cells. Med Sci Monit. 26:e9244352020. View Article : Google Scholar : PubMed/NCBI